Significantly Improving the Bioefficacy for Rheumatoid Arthritis with Supramolecular Nanoformulations
Chao Ma,Bo Li,Jinrui Zhang,Yao Sun,Jingjing Li,Hangcheng Zhou,Jianlei Shen,Rui Gu,Jiangchao Qian,Chunhai Fan,Hongjie Zhang,Kai Liu
DOI: https://doi.org/10.1002/adma.202100098
IF: 29.4
2021-03-17
Advanced Materials
Abstract:As a typical inflammatory disease with chronic pain syndromes, rheumatoid arthritis (RA) generally requires long-term treatment with frequent injection administration at 1-2 times per day, because common medications such as interleukin1 receptor antagonist (IL1ra) have poor bioavailability and very limited half-life residence. Here a novel strategy to fabricate nanotherapeutic formulations employing genetically engineered IL1ra protein complexes, yielding ultralong-lasting bioefficacy is developed rationally. Using rat models, it is shown that these nanotherapeutics significantly improved drug regimen to a single subcutaneous administration in a 14-day therapy, suggesting their extraordinary bioavailability and ultralong-acting pharmacokinetics. Specifically, the half-life and bioavailability of the nanoformulations are boosted to the level of 30 h and by 7 times, respectively, significantly greater than other systems. This new strategy thus holds great promise to potently improve patient compliance in RA therapy, and it can be adapted for other therapies that suffer similar drawbacks.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology